volume 24, issue 2, P285-306 2010
DOI: 10.1016/j.idc.2010.01.006
View full text
|
|
Share

Abstract: The armamentarium of biologic therapies targeting specific elements of the immune system is rapidly expanding. This review describes the spectrum of infectious complications associated to date with each of the immunomodulating biologic therapies approved by the US Food and Drug Administration.